Figure 6.
The actions of 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS) are not through modulation of the Type I IFN receptor (IFNAR). BEAS-2B cells were infected with human rhinovirus (HRV) (MOI 3) (a-c), then treated with SAPS; or pre-treated with SAPS for 1 h prior to the addition of IFN-β (10 and 100 ng ml−1) (d-f). Whole-cell lysates were collected at 24 h. A representative blot of three (c) or four (f) independent experiments is shown. Data shown are mean±s.e.m. (n=3 for a and b, and n=4 for d and e). Significant differences are indicated by **P<0.01, ***P<0.001, and ****P<0.0001.